Radiopharm Theranostics Director Increases Shareholding

The latest announcement is out from Radiopharm Theranostics Limited ( (AU:RAD) ).

Radiopharm Theranostics Limited announced a change in the director’s interest notice, indicating that Director Ian Turner has acquired an additional 3,000,000 shares indirectly through a superannuation fund. This acquisition, conducted via on-market trade as RADX American Depositary Shares on NASDAQ, increases his total indirect holding to 6,724,697 shares. This move could potentially strengthen the director’s influence within the company and reflect confidence in its future prospects.

The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.

More about Radiopharm Theranostics Limited

Radiopharm Theranostics Limited operates in the healthcare industry, focusing on the development and commercialization of radiopharmaceutical products for diagnostic and therapeutic purposes. The company is listed on the Australian Securities Exchange under the ticker RAD.

Average Trading Volume: 6,021,358

Technical Sentiment Signal: Sell

Current Market Cap: A$53.68M

For a thorough assessment of RAD stock, go to TipRanks’ Stock Analysis page.